Massmutual Trust Co. FSB ADV Sells 202 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Massmutual Trust Co. FSB ADV lessened its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 0.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,587 shares of the medical research company’s stock after selling 202 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Quest Diagnostics were worth $3,092,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. State of Michigan Retirement System boosted its stake in Quest Diagnostics by 0.3% during the fourth quarter. State of Michigan Retirement System now owns 33,417 shares of the medical research company’s stock worth $4,608,000 after buying an additional 100 shares during the period. Arizona State Retirement System boosted its stake in Quest Diagnostics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 30,847 shares of the medical research company’s stock worth $4,253,000 after buying an additional 289 shares during the period. Private Trust Co. NA boosted its stake in Quest Diagnostics by 198.2% during the fourth quarter. Private Trust Co. NA now owns 1,139 shares of the medical research company’s stock worth $157,000 after buying an additional 757 shares during the period. International Assets Investment Management LLC boosted its stake in Quest Diagnostics by 207.2% during the fourth quarter. International Assets Investment Management LLC now owns 77,994 shares of the medical research company’s stock worth $10,754,000 after buying an additional 52,609 shares during the period. Finally, Alpine Woods Capital Investors LLC boosted its stake in Quest Diagnostics by 2.1% during the fourth quarter. Alpine Woods Capital Investors LLC now owns 30,442 shares of the medical research company’s stock worth $4,197,000 after buying an additional 633 shares during the period. Institutional investors own 88.06% of the company’s stock.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the completion of the transaction, the senior vice president now directly owns 5,019 shares in the company, valued at $718,118.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.79% of the stock is currently owned by corporate insiders.

Quest Diagnostics Stock Down 2.9 %

Shares of DGX stock traded down $4.39 on Monday, hitting $145.69. The stock had a trading volume of 1,261,942 shares, compared to its average volume of 1,000,710. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. The business has a 50 day moving average price of $141.41 and a 200 day moving average price of $134.77. The company has a market cap of $16.22 billion, a PE ratio of 20.20, a P/E/G ratio of 2.69 and a beta of 0.89. Quest Diagnostics Incorporated has a one year low of $119.59 and a one year high of $151.78.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.31 by $0.04. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.30 earnings per share. Research analysts anticipate that Quest Diagnostics Incorporated will post 8.89 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, July 22nd. Shareholders of record on Monday, July 8th were issued a $0.75 dividend. The ex-dividend date was Monday, July 8th. This represents a $3.00 dividend on an annualized basis and a yield of 2.06%. Quest Diagnostics’s dividend payout ratio is presently 40.38%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “neutral” rating in a research note on Monday, July 29th. Mizuho boosted their target price on shares of Quest Diagnostics from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. UBS Group boosted their target price on shares of Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Citigroup raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $165.00 in a research note on Wednesday, July 10th. Finally, StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 23rd. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $150.58.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.